Viking Therapeutics Files 8-K: Auditor Change
Ticker: VKTX · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1607678
Sentiment: neutral
Topics: auditor-change, regulatory-filing
Related Tickers: VKTX
TL;DR
Viking Therapeutics changed its auditor, filing an 8-K on 4/23.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on April 23, 2025, reporting events as of April 18, 2025. The filing primarily concerns changes in the registrant's certifying accountant and includes other events and financial statements/exhibits. No specific financial figures or new material events beyond the change in auditor were detailed in the provided text.
Why It Matters
A change in a company's certifying accountant can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: low — The filing primarily reports a change in the company's auditor, which is a standard procedural event and does not inherently indicate significant risk.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- April 23, 2025 (date) — Filing Date
- April 18, 2025 (date) — Earliest Event Date
FAQ
What is the primary reason for Viking Therapeutics filing this 8-K?
The primary reason for the filing is to report changes in the registrant's certifying accountant, along with other events and financial statements/exhibits.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on April 18, 2025.
What is Viking Therapeutics' principal executive office address?
Viking Therapeutics' principal executive office is located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California, 92121.
What is Viking Therapeutics' telephone number?
Viking Therapeutics' telephone number is 858-704-4660.
What is the SIC code for Viking Therapeutics?
The Standard Industrial Classification (SIC) code for Viking Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding Viking Therapeutics, Inc. (VKTX).